Trending Topics

Loading trending topics...

See what’s trending right now
Clean energyin Financial Markets
3 hours ago

XCF boosts renewable fuel production with a new facility, Sabien Tech sees strong order growth, and Australia may transform critical mineral supply chains, signaling progress in green energy and tech sectors.

Retail F&O traders lose Rs 1.1 lakh crore in FY25, 41% rise

Times of IndiaMonday, July 7, 2025 at 10:19:55 PM
Retail F&O traders lose Rs 1.1 lakh crore in FY25, 41% rise
Indian retail traders took a massive hit in the stock market’s futures and options (F&O) segment last fiscal year, losing a staggering ₹1.1 lakh crore—a 41% jump from the year before. Even though trading volumes dipped slightly after SEBI tightened rules, a shocking 91% of retail investors still ended up in the red.
Editor’s Note: This isn’t just another market stat—it’s a wake-up call. F&O trading is often glamorized as a fast track to wealth, but these numbers show how brutally risky it is for everyday investors. With nearly everyone losing money, it raises questions about whether retail traders truly understand these complex instruments or if more safeguards are needed. If you’ve ever been tempted by the "get rich quick" hype around derivatives, this story might make you think twice.
— Curated via WP Now’s

Was this article worth reading? Share it

Latest from Financial Markets
Trump’s Megabill Gives Chinese EV Makers a Leg Up, Says Head of Auto Group
negativeFinancial Markets
The head of a major Chinese auto group claims that Trump's proposed "megabill" would actually benefit Chinese EV makers by cutting subsidies for electric vehicles in the U.S. while favoring gas-powered cars. The argument is that this could make Chinese EVs more competitive globally if American incentives dry up.
Editor’s Note: If the U.S. scales back support for electric vehicles, it could inadvertently hand an advantage to China, which is already dominating the EV market. This isn’t just about cars—it’s a glimpse into how trade policies can backfire, reshaping global competition in ways lawmakers might not intend.
‘Tiger King’ cat wrangler ‘Doc’ Antle faces up to 10 years in prison in South Carolina sentencing
negativeFinancial Markets
Bhagavan "Doc" Antle, the flamboyant big cat breeder made infamous by Netflix's Tiger King, is staring down a possible decade behind bars after being sentenced in South Carolina for wildlife trafficking and money laundering. The quote about buying a monkey with cash—pulled from the case—hints at the shady dealings that landed him in hot water.
Editor’s Note: Antle’s sentencing isn’t just about one eccentric character—it’s a signal that authorities are cracking down on the exploitative exotic animal trade. His case exposes how loosely regulated private zoos and breeders can fuel illegal wildlife trafficking, something conservationists have warned about for years. For fans of the Tiger King saga, it’s a grim but necessary footnote.
BioSig stock soars after securing up to $1.1B in growth financing
positiveFinancial Markets
BioSig’s stock shot up after the company announced it secured a massive financing deal—up to $1.1 billion—to fuel its growth. Investors are clearly betting big on the company’s future, sending shares soaring in response to the news.
Editor’s Note: This isn’t just a win for BioSig—it’s a signal that investors see serious potential in whatever they’re working on. A deal this size could mean major expansions, new projects, or even acquisitions down the line. For anyone watching the biotech or medtech space, this is a headline worth noting.
Soleno Therapeutics stock price target raised to $115 by Stifel on strong Vykat demand
positiveFinancial Markets
Stifel, a major investment firm, just bumped up its price target for Soleno Therapeutics' stock to $115, signaling strong confidence in the company. The boost comes as demand for Vykat, one of Soleno's key drugs, looks promising. Investors are clearly betting on growth here.
Editor’s Note: When analysts raise price targets like this, it’s usually a big vote of confidence—especially in the volatile biotech sector. If Vykat’s demand stays strong, Soleno could be in for a solid run. For anyone tracking pharma stocks or growth opportunities, this is worth keeping an eye on.
ZyVersa's VAR 200 approved for emergency use in rare kidney disease
positiveFinancial Markets
ZyVersa just got the green light for emergency use of its drug VAR 200, targeting a rare and serious kidney disease. This is a big win for patients with limited treatment options—think of it as a fast-tracked lifeline while full approval is still in the works.
Editor’s Note: Rare diseases often get left behind in the drug development race, so emergency approvals like this can be game-changers. For families dealing with this condition, it’s not just another headline—it’s hope for more time and better outcomes. The catch? It’s still early days, but it’s a step forward where steps are hard to come by.

Why World Pulse Now?

Global Coverage

All major sources, one page

Emotional Lens

Feel the mood behind headlines

Trending Topics

Know what’s trending, globally

Read Less, Know More

Get summaries. Save time

Stay informed, save time
Learn more

Live Stats

Articles Processed

8,283

Trending Topics

168

Sources Monitored

211

Last Updated

3 hours ago

Live data processing
How it works

Mobile App

Available on Android

The mobile app adds more ways to stay informed — including offline reading, voice-enabled summaries, and personalized trend alerts.

Get it on Google PlayDownload on the App Store
Available now on Android. iOS coming soon.

1-Minute Daily Briefing

Stay sharp in 60 seconds. Get concise summaries of today’s biggest stories — markets, tech, sports, and more

By subscribing, you agree to our Privacy Policy